Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

Review
.2010 Jul-Aug;77(4):374-80.
doi: 10.1002/msj.20199.

Role of antibodies in developing drugs that target G-protein-coupled receptor dimers

Affiliations
Review

Role of antibodies in developing drugs that target G-protein-coupled receptor dimers

Chris Hipser et al. Mt Sinai J Med.2010 Jul-Aug.

Abstract

G-protein-coupled receptors are important molecular targets in drug discovery. These receptors play a pivotal role in physiological signaling pathways and are targeted by nearly 50% of currently available drugs. Mounting evidence suggests that G-protein-coupled receptors form dimers, and various studies have shown that dimerization is necessary for receptor maturation, signaling, and trafficking. However, the physiological implications of dimerization in vivo have not been well explored because detection of GPCR dimers in endogenous systems has been a challenging task. One exciting new approach to this challenge is the generation of antibodies against specific G-protein-coupled receptor dimers. Such antibodies could be used as tools for characterization of heteromer-specific function; as reagents for their purification, tissue localization, and regulation in vivo; and as probes for mapping their functional domains. In addition, such antibodies could serve as alternative ligands for G-protein-coupled receptor heteromers. Thus, heteromer-specific antibodies represent novel tools for the exploration and manipulation of G-protein-coupled receptor-dimer pharmacology.

2010 Mount Sinai School of Medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A monoclonal antibody can be generated that specifically recognizes receptor heteromers, but not homomers. It can be used as a tool to detect receptor heteromers in vivo and to characterize heteromer-specific signaling.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosc. 2001;2(4):274–286. - PubMed
    1. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G-protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol. 2002;42:409–435. - PubMed
    1. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov. 2002;1(10):808–20. - PubMed
    1. Milligan G. Gprotein-coupled receptor dimerization:Function and ligand pharmacology. Mol Pharmacol. 2004;66(1):1–7. - PubMed
    1. Devi LA. G-protein-coupled receptor dimers in the lime light. Trends Pharmacol Sci. 2000;21(9):324–326. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp